Acute phase reaction to bisphosphonates

Authors

  • Cátia Pereira Centro Hospitalar Universitário de Coimbra. Coimbra. Portugal
  • Joana Costa Centro Hospitalar Universitário de Coimbra. Coimbra. Portugal
  • Diana Aguiar Centro Hospitalar Baixo Vouga. Aveiro. Portugal
  • Joana Coelho Centro Hospitalar Universitário de Coimbra. Coimbra. Portugal

DOI:

https://doi.org/10.32818/reccmi.a4n2a11

Keywords:

febrile syndrome, bisphosphonates, osteoporosis, acute phase reaction.

Abstract

Osteoporosis affects a large number of patients and has a major functional impact on daily activities. The intake of bisphosphonates, reduce bone resorption with clinical benefits and limited adverse effects. The acute phase reaction is one dosedependent side effect of this drug, it is characterized by one febrile syndrome including myalgias with a good response to analgesics. The authors present one patient who, after taking bisphosphonates, started fever, headaches and myalgias, which disappeared after suspension. Being this an unusual adverse effect, it is important to stay alert to these reactions, which are an exclusion diagnosis and should not be forgotten.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Rizzoli R, Reginster JY, Boonen S, Bréart G, Díez-Pérez A, Felsenberg D, et al. Adverse reactions and drug–Drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011; 89(2): 91-104. doi: https://doi.org/10.1007/s00223-011-9499-8.

Hamdy RC. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther. 2010; 4: 321-335. doi: https://doi.org/10.2147/DDDT.S6287.

Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, et al. Bisphos- phonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug revents And Reports (RADAR) Project. J Bone Joint Surg Am. 2013; 95(4): 297-307. doi: https://doi.org/10.2106/JBJS.K.01181.

Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing? Injury. 2016; 47(1): S65-S68. doi: https://doi.org/10.1016/S0020-1383(16)30015-8.

Papapetrou PD. Biphosphonate-associated adverse events. Hormones. 2009; 8(2): 96-110. doi: https://doi.org/10.14310/horm.2002.1226.

Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to amin- obisphosphonates is inhibited by statins. Clin Exp Immunol. 2005; 139(1): 101-111. doi: https://doi.org/10.1111/j.1365-2249.2005.02665.x.

Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009; 84(7): 632-638. doi: https://doi.org/10.1016/S0025-6196(11)60752-0.

Published

2019-08-31

How to Cite

1.
Pereira C, Costa J, Aguiar D, Coelho J. Acute phase reaction to bisphosphonates. Rev Esp Casos Clin Med Intern [Internet]. 2019 Aug. 31 [cited 2024 Nov. 25];4(2):73-5. Available from: https://www.reccmi.com/RECCMI/article/view/389